Delivering Therapy Beyond the Trial Setting

This segment addresses the discomfort of moving infusion care off the trial model, where axatilimab was delivered at academic centers. Faculty argue that clinical expertise and a sound understanding of the trial can responsibly guide administration in community and home settings, provided the benefits and risks are weighed for each patient. The shared approach is consistent: start patients at the treating center, confirm tolerability through the early doses, then transition once stable, since problems tend to surface early and remain uncommon. Faculty are candid that home infusion is not universally preferred. Some patients value the social contact and routine of the infusion center, and selection depends on reliability, clinical stability, and support at home. Practical advantages are also noted, including the ability to hand insurance coordination to home health, which can ease the treating team's authorization burden. The segment frames off-trial delivery as feasible when guided by judgment and careful patient selection.